Of the 231 breast carcinoma cases examined, LUMA comprised 9 (3.9%), LUMB 37 (16.0%), HER2 40 (17.3%), basal 23 (10.0%) and unclassified (penta negative) 99 (42.8%). This evidence concerns the gene ERBB2 and breast carcinoma.